|Min SIP Amount||Not Supported|
|NAV||₹10.79 (14 Jan 2021)|
|Fund Started||27 Mar 2018|
|Fund Size||₹277 Cr|
|Mahindra & Mahindra Ltd.||Automobile||Equity||6.1%|
|Bharti Airtel Ltd.||Communication||Equity||5.9%|
|Colgate-Palmolive (India) Ltd.||FMCG||Equity||5.2%|
|PI Industries Ltd.||Chemicals||Equity||5.1%|
|Chambal Fertilisers & Chemicals Ltd.||Chemicals||Equity||5.0%|
|Mahindra & Mahindra Financial Services Ltd.||Financial||Equity||5.0%|
|Coromandel International Ltd.||Chemicals||Equity||4.7%|
|Rallis India Ltd.||Chemicals||Equity||4.0%|
UTI Long Term Advantage Fund Series VII Regular Growth is a Equity Mutual Fund Scheme launched by UTI Mutual Fund. This scheme was made available to investors on 27 Mar 2018. Lalit Nambiar is the Current Fund Manager of UTI Long Term Advantage Fund Series VII Regular Growth fund.The fund currently has an Asset Under Management(AUM) of ₹277 Cr and the Latest NAV as of 14 Jan 2021 is ₹10.79.
The UTI Long Term Advantage Fund Series VII Regular Growth is rated Moderately High risk. Minimum SIP Investment is set to 500.
The investment objective of the scheme is to provide medium to long term capital appreciation along with income tax benefit.
Upto Rs. 1.5 lac will be tax free under 80C. Lockin of 3 years. Returns will be taxed at 10%.